With globalization as a strategy and following the dual path of imitation and innovation, we established the widely known brands of “BaiShiXin” and “TianLiWei.” Our first sustained-release drug has entered the US market. Our generic drugs business has seen rapid growth because of our integration of APIs and drug manufacturing, volume-based procurement, high technological barrier and differentiation strategy. We seek to bring clinical efficacy in our drug development, both through collaborative and proprietary research and development. Our work has breakthroughs in cardiovascular medicine, anti-cancer treatment and immunotherapy.
